Cefixime – 3rd generation oral cephalosporin for children Case report

Article Sidebar

Requires Subscription PDF (Język Polski)
Purchase article

Published: Sep 30, 2022
DOI: https://doi.org/10.24292/01.MF.0322.10
Keywords:
cefixime, efficacy, safety, respiratory tract infections, urinary tract infections, children

Main Article Content

Adam J. Sybilski
1. II Klinika Pediatrii, Centrum Medyczne Kształcenia Podyplomowego w Warszawie. 2. Klinika Chorób Dziecięcych i Noworodkowych, Centralny Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji w Warszawie
Małgorzata Kudan
Klinika Chorób Dziecięcych i Noworodkowych, Centralny Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji w Warszawie

Abstract

Cefixime is a semi-synthetic β-lactam antibiotic, a third-generation cephalosporin for oral use, both in children (registration from 6 months of age) and in adults. It has a strong bactericidal effect by inhibiting the biosynthesis of the bacterial cell wall. The spectrum of activity is Streptococcus pyogenes, Haemophilus influenzae, Moraxella catarrhalis, Proteus mirabilis. Clinical indications for the use of cefixime in children are community acquired pneumonia, lower urinary tract infections, pyelonephritis, otitis media, sinusitis, pharyngitis. The data from clinical trials clearly show the high effectiveness of the antibiotic in children and adolescents, while demonstrating high safety and rare side effects (mainly gastrointestinal symptoms). Due to the pharmacokinetic and pharmacodynamic properties, the antibiotic can be administered once a day, regardless of meals.


This article describes three common use cases of cefixime in children. Children treated for pyelonephritis, community-acquired pneumonia, and acute otitis media are shown. Efficacy, safety, bioavailability, good taste, and an easy dosing regimen make cefixime an appropriate antibiotic option in children.

Article Details

How to Cite
Sybilski , A. J., & Kudan, M. (2022). Cefixime – 3rd generation oral cephalosporin for children. Medycyna Faktow (J EBM), 15(3(56), 330-332. https://doi.org/10.24292/01.MF.0322.10
Issue
Vol 15 No 3(56) (2022)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Brogden RN, Campoli-Richards DM. Cefixime. A review of its antibacterial activity. Pharmacokinetic properties and therapeutic potential. Drugs. 1989; 38(4): 524-50.
2. Markham A, Brogden RN. Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections. Drugs. 1995; 49(6): 1007-22.
3. Long SS. Cefixime. Pediatr Ann. 1993; 22(3): 177-81, 185-6.
4. Sengupta J, Mondal AK, Jain P et al. Comparative evaluation of cefpodoxime versus cefixime in children with lower respiratory tract infections. Indian J Pediatr. 2004; 71(6): 517-21.
5. Bluestone CD. Review of cefixime in the treatment of otitis media in infants and children. Pediatr Infect Dis J. 1993; 12(1): 75-82.
6. Naber KG. Cefixime in urinary tract infections. (Specific studies and literature review). Infection. 1990; 18(suppl 3): S132-9.
7. Bader MS, Loeb M, Leto D et al. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgrad Med. 2020; 132(3): 234-50.
8. Wasilewska A (ed). Zalecenia Polskiego Towarzystwa Nefrologii Dziecięcej (PTNFD) dotyczące postępowania z dzieckiem z zakażeniem układu moczowego. PTNFD, Białystok 2021.
9. Hryniewicz W, Albrecht P, Radzikowski A (ed). Rekomendacje postępowania w pozaszpitalnych zakażeniach układu oddechowego. Narodowy Instytut Leków, Warszawa 2016.